Literature DB >> 34866539

What are the key challenges in the pharmacological management of cholangiocarcinoma?

Matthew Ledenko1, Tushar Patel1.   

Abstract

Entities:  

Keywords:  Biliary tract cancers; chemotherapy; immunotherapy; molecular targeted therapy

Mesh：

Year:  2021        PMID： 34866539      PMCID： PMC8930540          DOI： 10.1080/14656566.2021.2010707

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN： 1465-6566            Impact factor:   3.889


× No keyword cloud information.
  14 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

3.  Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.

Authors:  R Bahleda; F Meric-Bernstam; L Goyal; B Tran; Y He; I Yamamiya; K A Benhadji; I Matos; H-T Arkenau
Journal:  Ann Oncol       Date:  2020-07-02       Impact factor: 32.976

4.  Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.

Authors:  A Demols; I Borbath; M Van den Eynde; G Houbiers; M Peeters; R Marechal; T Delaunoit; J-C Goemine; S Laurent; S Holbrechts; M Paesmans; J-L Van Laethem
Journal:  Ann Oncol       Date:  2020-05-25       Impact factor: 32.976

5.  Phase 2 Trial of Adjuvant Chemotherapy With S - 1 for Node-Positive Biliary Tract Cancer (N-SOG 09).

Authors:  Kazuaki Seita; Tomoki Ebata; Takashi Mizuno; Atsuyuki Maeda; Ryuzo Yamaguchi; Yasuhiro Kurumiya; Eiji Sakamoto; Kazuhiro Hiramatsu; Masahiko Ando; Masato Nagino
Journal:  Ann Surg Oncol       Date:  2020-03-16       Impact factor: 5.344

6.  Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Authors:  Ghassan K Abou-Alfa; Vaibhav Sahai; Antoine Hollebecque; Gina Vaccaro; Davide Melisi; Raed Al-Rajabi; Andrew S Paulson; Mitesh J Borad; David Gallinson; Adrian G Murphy; Do-Youn Oh; Efrat Dotan; Daniel V Catenacci; Eric Van Cutsem; Tao Ji; Christine F Lihou; Huiling Zhen; Luis Féliz; Arndt Vogel
Journal:  Lancet Oncol       Date:  2020-03-20       Impact factor: 41.316

7.  Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

Authors:  Vivek Subbiah; Ulrik Lassen; Elena Élez; Antoine Italiano; Giuseppe Curigliano; Milind Javle; Filippo de Braud; Gerald W Prager; Richard Greil; Alexander Stein; Angelica Fasolo; Jan H M Schellens; Patrick Y Wen; Kert Viele; Aislyn D Boran; Eduard Gasal; Paul Burgess; Palanichamy Ilankumaran; Zev A Wainberg
Journal:  Lancet Oncol       Date:  2020-08-17       Impact factor: 41.316

8.  Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Authors:  Ghassan K Abou-Alfa; Teresa Macarulla; Milind M Javle; Robin K Kelley; Sam J Lubner; Jorge Adeva; James M Cleary; Daniel V Catenacci; Mitesh J Borad; John Bridgewater; William P Harris; Adrian G Murphy; Do-Youn Oh; Jonathan Whisenant; Maeve A Lowery; Lipika Goyal; Rachna T Shroff; Anthony B El-Khoueiry; Bin Fan; Bin Wu; Christina X Chamberlain; Liewen Jiang; Camelia Gliser; Shuchi S Pandya; Juan W Valle; Andrew X Zhu
Journal:  Lancet Oncol       Date:  2020-05-13       Impact factor: 41.316

9.  Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.

Authors:  Rachna T Shroff; Milind M Javle; Lianchun Xiao; Ahmed O Kaseb; Gauri R Varadhachary; Robert A Wolff; Kanwal P S Raghav; Michiko Iwasaki; Peter Masci; Ramesh K Ramanathan; Daniel H Ahn; Tanios S Bekaii-Saab; Mitesh J Borad
Journal:  JAMA Oncol       Date:  2019-06-01       Impact factor: 31.777

10.  Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results.

Authors:  Makoto Ueno; Masafumi Ikeda; Takashi Sasaki; Fumio Nagashima; Nobumasa Mizuno; Satoshi Shimizu; Hiroki Ikezawa; Nozomi Hayata; Ryo Nakajima; Chigusa Morizane
Journal:  BMC Cancer       Date:  2020-11-16       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.